Gestational Trophoblastic Disease is a group of conditions related to pregnancy. It involves abnormal growth of the tissue that normally forms the placenta. This tissue, called trophoblast, can grow too much or become cancerous. It's important to get diagnosed and treated promptly if you have this condition.
Every report comes from a Lived member, sent anonymously.
Have you had Vacuum Curettage for Gestational Trophoblastic Disease?
Gestational trophoblastic disease (GTD) is a group of rare conditions in which tissue that should become part of the placenta grows abnormally inside the uterus after conception. This tissue is made of trophoblast cells, which normally attach a pregnancy to the wall of the uterus. In GTD, a problem at fertilization means these cells form an abnormal growth, and a healthy pregnancy cannot develop. The most common form is a molar pregnancy, also called a hydatidiform mole. In a complete mole there is no fetus. In a partial mole some fetal tissue forms, but it cannot develop into a baby. Molar pregnancies are not cancer, but abnormal tissue can remain and keep growing after the pregnancy ends. A molar pregnancy is also a pregnancy loss, and many people experience it that way. When trophoblast tissue persists, grows into the wall of the uterus or spreads, it is called gestational trophoblastic neoplasia (GTN). This group includes invasive mole and choriocarcinoma, along with two very rare, slower-growing tumors: placental-site trophoblastic tumor and epithelioid trophoblastic tumor. GTN is a cancer, but it is one of the most treatable: with proper care, nearly everyone who has it can expect to be cured. Most forms of GTD produce human chorionic gonadotropin (hCG), the pregnancy hormone that home pregnancy tests detect. Measuring that hormone in the blood is central to how GTD is found, treated and followed.
A molar pregnancy starts with an error at fertilization, not with anything either parent did. A complete mole forms when sperm fertilizes an egg that carries none of the mother's genetic material, so all of it comes from the father. A partial mole forms when an egg ends up with two sets of the father's genetic material alongside the mother's. In both cases the placental tissue overgrows and the pregnancy cannot develop normally. There is no known way to prevent it. Age at either end of the reproductive years is the clearest risk factor. Teenagers and people over 35 have about twice the risk of those aged 20 to 35, and the risk is five to seven times higher after 40. Molar pregnancy is more common in parts of Asia, Africa and Central America than in the United States, where it occurs in fewer than 1 in 1,000 deliveries. After one molar pregnancy, the chance of another is low, roughly 1 to 2 in 100, but it rises after two in a row. Rare inherited gene changes have been found in women who have repeated molar pregnancies. GTN most often develops from a molar pregnancy. It follows about 13 to 20 in 100 complete moles and fewer than 5 in 100 partial moles. About a quarter of GTN cases, though, follow a miscarriage, an ectopic pregnancy (one that implants outside the uterus) or, more rarely, a full-term birth, sometimes long after that pregnancy ended.
Most molar pregnancies are now found in the first trimester on an early ultrasound, often before any symptoms appear. When symptoms do occur, vaginal bleeding is the most common. Others include a uterus larger than expected for the stage of pregnancy, severe nausea and vomiting, high blood pressure early in pregnancy, and signs of an overactive thyroid such as a racing heart, shakiness and weight loss. These complications have become less common because molar pregnancies are now usually found early. On ultrasound, a complete mole typically shows no fetus and a placenta filled with small cysts, while a partial mole may show a cystic placenta alongside some fetal tissue. Blood hCG is often higher than expected for the stage of pregnancy. Ultrasound can strongly suggest a mole, but the diagnosis is confirmed by examining the tissue under a microscope after it is removed. This is one reason tissue from a miscarriage is often sent for testing too. GTN is usually diagnosed during hCG follow-up after a molar pregnancy, often before there are any symptoms. Normally, hCG falls steadily once the tissue is removed. What matters is the direction of the trend, not a single number. GTN is diagnosed when weekly results stop falling (four readings over three weeks that stay roughly level) or start rising (three weekly readings in a row going up), or when tissue shows choriocarcinoma. When GTN follows another kind of pregnancy, the first clue may be bleeding that continues long after delivery, or symptoms from spread such as breathing problems, combined with a raised hCG level in someone who is not pregnant. Once GTN is found, a chest X-ray and pelvic ultrasound, and sometimes computed tomography (CT) or magnetic resonance imaging (MRI) scans of the brain, abdomen and pelvis, show whether it has spread. Doctors assign a stage from I (confined to the uterus), through II (spread to the vagina or other genital organs outside the uterus) and III (spread to the lungs), to IV (spread elsewhere, for example to the liver or brain). They also calculate a risk score from factors such as age, hCG level, tumor size, time since the pregnancy, and the number and location of any spread. A score of 6 or below is low risk and 7 or above is high risk. The score largely decides how intensive the first chemotherapy needs to be.
A molar pregnancy is removed with suction evacuation, often called a suction D&C. The cervix is gently opened and the tissue is removed through a thin tube, usually under general anesthesia and ideally with ultrasound guidance. People who have finished having children may choose a hysterectomy (removal of the uterus) instead, which can usually leave the ovaries in place. A second D&C is not routine, and chemotherapy straight after removal is reserved for unusual situations, such as when reliable hCG follow-up is not possible. Low-risk GTN is treated with a single chemotherapy drug, either methotrexate or actinomycin D (also called dactinomycin), given by injection or into a vein in repeated cycles, usually every one to two weeks. In studies, actinomycin D has produced remission more often as a first drug, but it tends to cause more nausea, vomiting and hair thinning. About 3 in 10 people need to switch drugs because hCG stops falling, and most respond to the second drug. People at the upper end of the low-risk range who also have spread, choriocarcinoma or very high hCG are usually started on combination chemotherapy instead. Treatment continues for two to three cycles after hCG reaches normal to lower the chance of relapse, and cure rates for low-risk GTN approach 100%. High-risk GTN needs combination chemotherapy, most often a regimen called EMA-CO, named for the initials of its five drugs (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine), which are given in alternating weekly sets. It is more toxic than single-drug treatment. About 1 in 5 people need a different regimen because the first one stops working, and most of them are still cured. Overall survival for high-risk disease now exceeds 95% with treatment at an experienced center. Spread to the liver or brain makes treatment harder and may call for more intensive regimens. When GTN resists several chemotherapy regimens, options include immunotherapy drugs such as pembrolizumab, which help the immune system attack the tumor, and surgery to remove an isolated tumor that has not responded. Placental-site and epithelioid trophoblastic tumors respond less well to chemotherapy, so hysterectomy is their main treatment, with chemotherapy added if they have spread. Hysterectomy can also control severe bleeding, though it does not replace hCG monitoring. Because GTD is rare, care is best coordinated with a specialist or referral center that treats it regularly.
After a molar pregnancy is removed, the main task is follow-up. hCG blood tests are repeated every one to two weeks until the level returns to normal. After a partial mole, one more normal test a month later is usually enough. After a complete mole, testing continues monthly for six months after the level first becomes normal. GTN rarely develops once hCG has fallen to normal on its own, so for most people follow-up ends within months. Keeping every test matters, because a stalled or rising result is how GTN is caught early, when it is most easily treated. During follow-up, it is important not to become pregnant and to use reliable contraception, since a new pregnancy raises hCG and would hide a return of the disease. Hormonal birth control is considered safe during this time. After treatment for GTN, hCG is checked monthly for at least a year, with contraception throughout. Unless the uterus has been removed, future fertility and later pregnancies are typically not affected after evacuation or chemotherapy, and trying again is usually discussed once hCG follow-up is complete. The experience can be hard in ways that are not only physical. A molar pregnancy combines a pregnancy loss with weeks or months of testing and, for some, a cancer diagnosis and chemotherapy. Emotional recovery can take time. The care team can point to counseling and support services, and nursing and psychological support also help people stay on track with follow-up.
If you are pregnant, contact your midwife, obstetrician or doctor promptly about any vaginal bleeding or dark discharge, frequent vomiting that goes beyond ordinary morning sickness, or a bump that seems larger than it should be for the stage of pregnancy. After any pregnancy, including a miscarriage, see a doctor if vaginal bleeding continues longer than expected or a pregnancy test stays positive when you are not pregnant. During hCG follow-up or after treatment for GTN, contact your care team promptly if you miss a test, think you might be pregnant, or notice new vaginal bleeding, a new cough or breathlessness, or a new headache that will not go away, since these can be signs the disease has returned or spread. Molar tissue and GTN can bleed heavily, in the uterus or where the disease has spread to the lungs or brain. At any stage, call 911 for very heavy vaginal bleeding (soaking a pad soon after putting it on), bleeding with fainting or dizziness, a seizure, a sudden severe headache, sudden weakness or confusion, or sudden severe trouble breathing or coughing up blood.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Gestational Trophoblastic Disease is like, what's helped you, or ask the community a question.